VEGF pathway inhibitors-induced hypertension: next step in therapy
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't, Comment
PubMed
24890259
PubMed Central
PMC8031679
DOI
10.1111/jch.12348
Knihovny.cz E-resources
- MeSH
- Phenylurea Compounds adverse effects therapeutic use MeSH
- Hypertension chemically induced epidemiology MeSH
- Humans MeSH
- Neoplasms drug therapy MeSH
- Niacinamide analogs & derivatives MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Comment MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Phenylurea Compounds MeSH
- Niacinamide MeSH
- Antineoplastic Agents MeSH
See more in PubMed
Li Y, Li S, Zhu Y, et al. Incidence and risk of sorafenib‐induced hypertension: a systematic review and meta‐analysis. J Clin Hypertens (Greenwich). 2014;16:177–185. PubMed PMC
Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med. 1995;1:27–31. PubMed
Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis‐inhibitor‐induced hypertension. Angiogenesis. 2013;16:289–295. PubMed PMC
Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432–1439. PubMed PMC
Kruzliak P, Novak J, Novak M. Vascular endothelial growth factor inhibitor‐induced hypertension: from pathophysiology to prevention and treatment based on long‐acting nitric oxide donors. Am J Hypertens. 2014;27:3–13. PubMed
Montero AJ, Escobar M, Lopes G, et al. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep. 2012;14:1–11. PubMed PMC
